Shanshan Liu

ORCID: 0000-0003-3080-7465
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer-related molecular mechanisms research
  • RNA modifications and cancer
  • MicroRNA in disease regulation
  • Cancer, Hypoxia, and Metabolism
  • Extracellular vesicles in disease
  • RNA Research and Splicing
  • RNA Interference and Gene Delivery
  • Circular RNAs in diseases
  • Ferroptosis and cancer prognosis
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Wnt/β-catenin signaling in development and cancer
  • Bioinformatics and Genomic Networks
  • Nanoplatforms for cancer theranostics
  • Melanoma and MAPK Pathways
  • Cancer Genomics and Diagnostics
  • interferon and immune responses
  • Chromosomal and Genetic Variations
  • Ubiquitin and proteasome pathways
  • Cancer-related gene regulation
  • Cutaneous Melanoma Detection and Management
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Research and Treatments
  • Microbial Metabolic Engineering and Bioproduction
  • Angiogenesis and VEGF in Cancer
  • Biochemical and Molecular Research

Second Affiliated Hospital of Chongqing Medical University
2023-2024

Tianjin Medical University
2024

Dalian Medical University
2023-2024

Chongqing Medical University
2021-2024

Second Affiliated Hospital of Xi'an Jiaotong University
2023

Xiangya Hospital Central South University
2022

Central South University
2022

The Affiliated Yongchuan Hospital of Chongqing Medical University
2021

Southern Medical University
2021

Shanghai Public Health Clinical Center
2021

Public summary•clusterProfiler supports exploring functional characteristics of both coding and non-coding genomics data for thousands species with up-to-date gene annotation•It provides a universal interface annotation from variety sources thus can be applied in diverse scenarios•It tidy to access, manipulate, visualize enrichment results help users achieve efficient interpretation•Datasets obtained multiple treatments time points analyzed compared single run, easily revealing consensus...

10.1016/j.xinn.2021.100141 article EN cc-by-nc-nd The Innovation 2021-07-01

Traditional treatments against advanced non-small cell lung cancer (NSCLC) with high morbidity and mortality continue to be dissatisfactory. Given this situation, there is an urgent requirement for alternative modalities that provide lower invasiveness, superior clinical effectiveness, minimal adverse effects. The combination of photodynamic therapy (PDT) immunotherapy gradually become a promising approach high-grade malignant NSCLC. Nevertheless, owing the absence precise drug delivery...

10.1016/j.bioactmat.2024.05.030 article EN cc-by-nc-nd Bioactive Materials 2024-05-21

Abstract Background tRNA-derived fragments (tRFs) have been shown to critical regulatory roles in cancer biology. However, the contributions of tRFs colorectal (CRC) remain largely unknown. Methods tRF3008A (a tRFRNA derived from tRNA Val ) was identified by RNA sequencing and validated quantitative reverse transcription PCR. The role CRC progression assessed both vitro vivo, its downstream target genes were cells. pull-down with mass spectrometry AGO-RIP used confirm interaction AGO...

10.1186/s13046-021-02190-4 article EN cc-by Journal of Experimental & Clinical Cancer Research 2022-01-22

Background: Therapeutic interventions such as synthetic drugs and microRNA (miR) modulators have created opportunities for mitigating hepatic ischemia/reperfusion injury (HIRI) by alleviating mitochondrial dysfunction.However, delivering multi-therapeutic ingredients with low toxicity to hepatocytes still lags behind its development.Methods: In this study, we endowed exosomes delivery function concentrate on multidimensionally halting mitochondria dysfunction during HIRI.Concretely, were...

10.7150/thno.88061 article EN cc-by Theranostics 2023-11-15

Background and aims: Vasoactive intestinal polypeptide type-I receptor (VIPR1) overexpression has been reported in numerous types of malignancies utilized to develop novel target therapeutics radiolabeled VIP analogue-based tumor imaging technology, but its role liver carcinogenesis not explored.In the current study, we investigated VIP/VIPR1 signaling controlling hepatocellular carcinoma (HCC) progression.Approach results: By analyzing clinical samples, found expression level VIPR1 was...

10.7150/ijbs.71134 article EN cc-by-nc International Journal of Biological Sciences 2022-01-01

Background: Endostatin therapy is known to efficiently inhibit angiogenesis and growth of endothelial cells. Nonetheless, the antitumor mechanisms endostatin combined with chemotherapy remain be elucidated. Methods: In our study, a Lewis lung carcinoma transplant mouse model was established treated recombinant human [rh]-endostatin, Endostar, gemcitabine at different sequences. 18F-FDG PET/CT imaging performed monitor tumor growth, hypoxia examined using an oxygen microelectrode. Vascular...

10.2147/cmar.s192868 article EN cc-by-nc Cancer Management and Research 2019-04-01

Background: Osteosarcoma (OS) is one of the malignant bone tumors occurring in both human and canine, them, it characterized by a high rate metastasis poor prognosis. Cross-species analysis reveals previously neglected molecular or signaling pathways involved progression diseases, dogs are genetically comparable to humans live similar environments. Therefore, aim this study was find out OS hub genes through cross-species analysis. Materials Methods: All canine gene expression data obtained...

10.3389/fgene.2019.00697 article EN cc-by Frontiers in Genetics 2019-08-07

The H/ACA small nucleolar ribonucleoprotein (snoRNP) gene family, including GAR1 (GAR1), NHP2 (NHP2), NOP10 (NOP10), and dyskerin pseudouridine synthase 1 (DKC1), play important roles in ribosome biogenesis. However, the potential clinical value of snoRNP family hepatocellular carcinoma (HCC) has not yet been reported.Bioinformation databases were used to analyze expression HCC. Survival analysis, Gene Ontology (GO), Kyoto Encyclopedia Genes Genomes enrichment pathway (KEGG) analyses...

10.2147/pgpm.s333838 article EN cc-by-nc Pharmacogenomics and Personalized Medicine 2021-10-01

// Shan-Shan Liu 1, * , Ning Meng-Yao 1 Lei Sun Wu-Yan Xia Hong-Min Lu Yu-Jie Fu Guo-Liang Yang 2 Juan-Jie Bo Xiao-Xing 3 Haizhong Feng Hailong Wu Lin-Feng Li and Jian-Xin Gao State Key Laboratory of Oncogenes Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School Medicine, Shanghai Jiao Tong University, Shanghai, China Department Urology, Radiotherapy, These authors have contributed equally to this work Correspondence to: Gao, email: jianxingao@sjtu.edu.cn...

10.18632/oncotarget.17553 article EN Oncotarget 2017-05-02
Coming Soon ...